BioCeramic Therapeutics (BCT), an emerging leader in the field of novel biomaterials for healthcare, has received £1.2 million of new investment as the Company prepares to commercialise its products in 2010.
Imperial Innovations has invested £300,000 and Longbow Capital, a new investor, has invested £400,000. Other investors in the round include Comvest Limited and the Esmee Fairbairn Foundation, both of whom are existing shareholders. In addition, Mark Rowan, a director of Imperial Innovations and a director of, and existing shareholder in, BioCeramic Therapeutics, has invested a further £20,000 in the round. This investment follows funding of £1.04 million in 2007.
BioCeramic Therapeutics has also recently appointed Dr Stephan Rietiker, a recognised leader in the global medical health sector, as Chairman.
BioCeramic Therapeutics is developing bioactive materials for orthopaedic and dental applications. Its first products are scheduled for launch in 2010 and include bone graft substitutes that will help treat bone diseases and difficult fractures.